

NEUROSCIENCE AND NEUROLOGICAL DISORDERS

&

PSYCHIATRY AND PSYCHOLOGICAL DISORDERS

June 28-29, 2018 | Dublin, Ireland

J Neurol Neurorehabil Res 2018, Volume 3

NEWER ADVANCES IN NEUROPSYCHIATRY

Shashita Inamdar

Achieve Concierge, USA

The increasing prevalence of neuropsychiatric disorders in the last 20 years has called for a demand in new diagnostic and treatment options. The World Health Organization (WHO) labels mental disorders as a continuing global burden, with an estimated 300 million affected by depression, 60 million affected by bipolar affective disorder, 21 million affected by schizophrenia and 47.5 million affected by dementia. Conventional methods of using medications to treat such disorders have developed a negative perception over time among patients and in the media. Most medications are now viewed as having addictive characteristics, short and long-term side effects, drug interactions, and at times as being ineffective. With resistance from patients and limited efficacy, clinicians and researchers turn to new and more advanced methods to help those struggling with such disorders. Pharmacogenetics, the study of the role of the genome in drug interaction and response, has allowed us to better understand why one's genetic makeup can enhance or inhibit their response to certain medications. Given insight to the effectiveness of neurotransmitter uptake channels and transporters or certain metabolism rates, clinicians may make more informed and accurate decisions for their patients. Outside of pharmacotherapy, many treatments now look to the process of restructuring the brain to aid the symptoms of neuropsychiatric disorders. Ketamine has gained recent popularity in the treatment of depression and other neuropsychiatric disorders, where it works at the synaptic level to increase neural connectivity, dendritic remodelling and synaptogenesis for long term effect. Neuromodulation methods, such as Transcranial Magnetic Stimulation (TMS), an FDA cleared, and CE marked non-medication treatment, Neurofeedback, an EEG based biofeedback and Hyperbaric Oxygen Therapy (HBOT), have also shown to be leading methods in remodelling the brain to alleviate symptoms and create long lasting change in the brain structure. By addressing not only the chemical component of the brain, but also the electrical, we are able to make far more progress in treating neuropsychiatrist disorders and provide many patients with new hope.

drsinamdar@achieveconcierge.com